Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation

Journal of Controlled Release

Volumn 156, Issue 2, 2011, Pages 246-257

  Botella, Pablo ^a   Abasolo, Ibane ^b   Fernández, Yolanda ^b   Muniesa, Carlos ^a   Miranda, Sonia ^b   Quesada, Manuel ^a   Ruiz, Jorge ^b   Schwartz Jr , Simó ^b   Corma, Avelino ^a  

^a INSTITUTO DE TECNOLOGÍA QUÍMICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biodistribution; Camptothecin; Cancer; Optical imaging; Silica nanoparticles; Tolerability

Indexed keywords

BIODISTRIBUTIONS; CAMPTOTHECINS; CANCER; OPTICAL IMAGING; SILICA NANOPARTICLES; TOLERABILITY;

BIOCOMPATIBILITY; BODY FLUIDS; CELL DEATH; DISEASES; DRUG DELIVERY; FLUORESCENCE; FLUOROPHORES; MOLECULAR BIOLOGY; OPTICAL IMAGE STORAGE; PH; SILICA; TUMORS;

NANOPARTICLES;

CAMPTOTHECIN; NANOPARTICLE; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CELL CYCLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; MICE; MODELS, MOLECULAR; NANOPARTICLES; SILICON DIOXIDE; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 81255160990     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.06.039     Document Type: Article

References (64)

1. J. Thompson, C.F. Stewart, and P.J. Houghton Animal models for studying the action of topoisomerase I targeted drugs Biochim. Biophys. Acta 1400 1998 301 319 (Pubitemid 28475111)
2. V.J. Venditto, and E.E. Simanek Cancer therapies utilizing the camptothecins: a review of the in vivo literature Mol. Pharm. 7 2010 307 349
3. Z. Mi, and T.G. Burke Differential interactions of camptothecin lactone and carboxylate forms with human blood components Biochemistry 33 1994 10325 10336 (Pubitemid 24281798)
4. J.A. Gottlieb, A.M. Guarino, J.B. Call, V.T. Oliverio, and J.B. Block Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880) Cancer Chemother. Rep. 54 1970 461 470
5. F.M. Muggia, P.J. Creaven, H.H. Hansen, M.H. Cohen, and O.S. Selawry Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies Cancer Chemother. Rep. 1 56 1972 515 521
6. C.G. Moertel, A.J. Schutt, R.J. Reitemeier, and R.G. Hahn Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer Cancer Chemother. Rep. 1 56 1972 95 101
7. M.L. Rothenberg Topoisomerase I inhibitors: review and update Ann. Oncol. 8 1997 837 855 (Pubitemid 27452081)
8. K.S. Cunha, M.L. Reguly, U. Graf, and H.H. Rodrigues de Andrade Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination Mutagenesis 17 2002 141 147 (Pubitemid 34232905)
9. A. Shenderova, T.G. Burke, and S.P. Schwendeman Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles Pharm. Res. 14 1997 1406 1414 (Pubitemid 27481072)
10. S.C. Yang, L.F. Lu, Y. Cai, J.B. Zhu, B.W. Liang, and C.Z. Yang Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Control. Release 59 1999 299 307 (Pubitemid 29238174)
11. B.B. Lundberg Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions Anticancer Drug Des. 13 1998 453 461 (Pubitemid 28334032)
12. R. Cortesi, E. Esposito, A. Maietti, E. Menegatti, and C. Nastruzzi Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion Int. J. Pharm. 159 1997 95 103 (Pubitemid 28062814)
13. H. Zhao, C. Lee, P. Sai, Y.H. Choe, M. Boro, A. Pendri, S. Guan, and R.B. Greenwald 20-O-acylcamptothecin derivatives: evidence for lactone stabilization J. Org. Chem. 65 2000 4601 4606 (Pubitemid 30620570)
14. R.B. Greenwald, A. Pendri, C. Conover, C. Gilbert, R. Yang, and J. Xia Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms J. Med. Chem. 39 1996 1938 1940 (Pubitemid 26157293)
15. M. Zamai, M. VandeVen, M. Farao, E. Gratton, A. Ghiglieri, M.G. Castelli, E. Fontana, R. D'Argy, A. Fiorino, E. Pesenti, A. Suarato, and V.R. Caiolfa Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy Mol. Cancer Ther. 2 2003 29 40
16. R. Bhatt, P. de Vries, J. Tulinsky, G. Bellamy, B. Baker, J.W. Singer, and P. Klein Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin J. Med. Chem. 46 2003 190 193 (Pubitemid 36043799)
17. M.E. Fox, S. Guillaudeu, J.M. Frechet, K. Jerger, N. Macaraeg, and F.C. Szoka Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates Mol. Pharm. 6 2009 1562 1572
18. J. Cheng, K.T. Khin, and M.E. Davis Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates Mol. Pharm. 1 2004 183 193
19. J. Cheng, K.T. Khin, G.S. Jensen, A. Liu, and M.E. Davis Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates Bioconjug. Chem. 14 2003 1007 1017 (Pubitemid 37152961)
20. T. Numbenjapon, J. Wang, D. Colcher, T. Schluep, M.E. Davis, J. Duringer, L. Kretzner, Y. Yen, S.J. Forman, and A. Raubitschek Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models Clin. Cancer Res. 15 2009 4365 4373
21. T. Schluep, J. Cheng, K.T. Khin, and M.E. Davis Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice Cancer Chemother. Pharmacol. 57 2006 654 662 (Pubitemid 43237851)
22. T. Schluep, J. Hwang, I.J. Hildebrandt, J. Czernin, C.H. Choi, C.A. Alabi, B.C. Mack, and M.E. Davis Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements Proc. Natl. Acad. Sci. U.S.A. 106 2009 11394 11399
23. M.E. Davis Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin Adv. Drug Deliv. Rev. 61 2009 1189 1192
24. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
25. J.R. McCarthy, and R. Weissleder Multifunctional magnetic nanoparticles for targeted imaging and therapy Adv. Drug Deliv. Rev. 60 2008 1241 1251
26. C.-H. Lee, S.-H. Cheng, Y.-J. Wang, Y.-C. Chen, N.T. Chen, J. Souris, C.-T. Chen, C.-Y. Mou, C.-S. Yang, and L.-W. Lo Near-infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution Adv. Funct. Mater. 19 2009 215 222
27. Y. Liu, H. Miyoshi, and M. Nakamura Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles Int. J. Cancer 120 2007 2527 2537 (Pubitemid 46651272)
28. J.M. Rosenholm, C. Sahlgren, and M. Linden Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles- opportunities & challenges Nanoscale 2 2010 1870 1883
29. I.I. Slowing, J.L. Vivero-Escoto, C.W. Wu, and V.S. Lin Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers Adv. Drug Deliv. Rev. 60 2008 1278 1288
30. J. Lu, M. Liong, J.I. Zink, and F. Tamanoi Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs Small 3 2007 1341 1346 (Pubitemid 47245524)
31. J. Lu, M. Liong, Z. Li, J.I. Zink, and F. Tamanoi Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals Small 6 2010 1794 1805
32. R.P. Bagwe, L.R. Hilliard, and W. Tan Surface modification of silica nanoparticles to reduce aggregation and nonspecific binding Langmuir 22 2006 4357 4362
33. C. Ahowesso, E. Piccolo, X.M. Li, S. Dulong, V. Hossard, R. La Sorda, E. Filipski, N. Tinari, F. Delaunay, S. Iacobelli, and F. Levi Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice Toxicol. Lett. 192 2010 395 401
34. D.E. Jenkins, Y.S. Hornig, Y. Oei, J. Dusich, and T. Purchio Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice Breast Cancer Res. 7 2005 R444 454
35. P.C. Black, A. Shetty, G.A. Brown, E. Esparza-Coss, A.R. Metwalli, P.K. Agarwal, D. McConkey, J.D. Hazle, and C.P. Dinney Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis BJU Int. 106 2010 1799 1804
36. S.P. Hudson, R.F. Padera, R. Langer, and D.S. Kohane The biocompatibility of mesoporous silicates Biomaterials 29 2008 4045 4055
37. E. Climent, R. Martinez-Mañez, F. Sancenon, M.D. Marcos, J. Soto, A. Maquieira, and P. Amoros Controlled delivery using oligonucleotide-capped mesoporous silica nanoparticles Angew. Chem. Int. Ed. 49 2010 7281 7283
38. J. Lu, E. Choi, F. Tamanoi, and J.I. Zink Light-activated nanoimpeller-controlled drug release in cancer cells Small 4 2008 421 426 (Pubitemid 351641616)
39. N.K. Mal, M. Fujiwara, and Y. Tanaka Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica Nature 421 2003 350 353 (Pubitemid 36157928)
40. R. Hernandez, H.R. Tseng, J.W. Wong, J.F. Stoddart, and J.I. Zink An operational supramolecular nanovalve J. Am. Chem. Soc. 126 2004 3370 3371 (Pubitemid 38372118)
41. H. Meng, M. Xue, T. Xia, Y.L. Zhao, F. Tamanoi, J.F. Stoddart, J.I. Zink, and A.E. Nel Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves J. Am. Chem. Soc. 132 2010 12690 12697
42. Y.L. Zhao, Z. Li, S. Kabehie, Y.Y. Botros, J.F. Stoddart, and J.I. Zink pH-operated nanopistons on the surfaces of mesoporous silica nanoparticles J. Am. Chem. Soc. 132 2010 13016 13025
43. Q. He, Z. Zhang, Y. Gao, J. Shi, and Y. Li Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles Small 5 2009 2722 2729
44. J. Lu, M. Liong, S. Sherman, T. Xia, M. Kovochich, A.E. Nel, J.I. Zink, and F. Tamanoi Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells Nanobiotechnology 3 2007 89 95
45. J.M. Rosenholm, E. Peuhu, J.E. Eriksson, C. Sahlgren, and M. Linden Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems Nano Lett. 9 2009 3308 3311
46. Z. Tao, B.B. Toms, J. Goodisman, and T. Asefa Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials Chem. Res. Toxicol. 22 2009 1869 1880
47. F. Lu, S.H. Wu, Y. Hung, and C.Y. Mou Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles Small 5 2009 1408 1413
48. J.L. Vivero-Escoto, I.I. Slowing, B.G. Trewyn, and V.S. Lin Mesoporous silica nanoparticles for intracellular controlled drug delivery Small 6 2010 1952 1967
49. I. Slowing, B.G. Trewyn, and V.S. Lin Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells J. Am. Chem. Soc. 128 2006 14792 14793 (Pubitemid 44851603)
50. Y.P. Tsao, P. D'Arpa, and L.F. Liu The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B Cancer Res. 52 1992 1823 1829
51. K.H. Min, K. Park, Y.S. Kim, S.M. Bae, S. Lee, H.G. Jo, R.W. Park, I.S. Kim, S.Y. Jeong, K. Kim, and I.C. Kwon Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy J. Control. Release 127 2008 208 218
52. X. He, K. Wang, and Z. Cheng In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 2010 349 366
53. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
54. R. Kumar, I. Roy, T.Y. Ohulchanskky, L.A. Vathy, E.J. Bergey, M. Sajjad, and P.N. Prasad In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles ACS Nano 4 2010 699 708
55. G. Xie, J. Sun, G. Zhong, L. Shi, and D. Zhang Biodistribution and toxicity of intravenously administered silica nanoparticles in mice Arch. Toxicol. 84 2009 183 190
56. J.S. Zhang, F. Liu, and L. Huang Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity Adv. Drug Deliv. Rev. 57 2005 689 698 (Pubitemid 40332597)
57. J.S. Souris, C.H. Lee, S.H. Cheng, C.T. Chen, C.S. Yang, J.A. Ho, C.Y. Mou, and L.W. Lo Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles Biomaterials 31 2010 5564 5574
58. A.A. Burns, J. Vider, H. Ow, E. Herz, O. Penate-Medina, M. Baumgart, S.M. Larson, U. Wiesner, and M. Bradbury Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine Nano Lett. 9 2009 442 448
59. X. He, H. Nie, K. Wang, W. Tan, X. Wu, and P. Zhang In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles Anal. Chem. 80 2008 9597 9603
60. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284 (Pubitemid 30122932)
61. S.D. Perrault, C. Walkey, T. Jennings, H.C. Fischer, and W.C. Chan Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 9 2009 1909 1915
62. K. Xiao, J. Luo, Y. Li, W. Xiao, J.S. Lee, A.M. Gonik, and K.S. Lam The passive targeting of polymeric micelles in various types and sizes of tumor models Nanosci. Nanotech. Lett. 2 2010 79 85
63. R. Garcia-Carbonero, and J.G. Supko Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins Clin. Cancer Res. 8 2002 641 661 (Pubitemid 34742090)
64. C.J. Gerrits, M.J. de Jonge, J.H. Schellens, G. Stoter, and J. Verweij Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development Br. J. Cancer 76 1997 952 962 (Pubitemid 27401951)